Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
G1 Therapeutics Inc
(NQ:
GTHX
)
7.120
+0.020 (+0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
966,988
Open
7.100
Bid (Size)
7.090 (138)
Ask (Size)
7.120 (89)
Prev. Close
7.100
Today's Range
7.100 - 7.120
52wk Range
1.080 - 7.120
Shares Outstanding
42,705,532
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
August 15, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
August 15, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Performance
YTD
+128.94%
+128.94%
1 Month
+82.10%
+82.10%
3 Month
+109.41%
+109.41%
6 Month
+209.57%
+209.57%
1 Year
+318.82%
+318.82%
More News
Read More
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX
August 09, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
August 07, 2024
Via
InvestorPlace
Analyst Ratings For G1 Therapeutics
June 13, 2024
Via
Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
August 09, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
August 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
August 08, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast
August 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Jumps Over 3%; Upstart Shares Spike Higher
August 07, 2024
Via
Benzinga
Exposures
Fossil Fuels
Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates
August 07, 2024
Via
Benzinga
Topics
Earnings
Exposures
Financial
GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders
August 07, 2024
From
Halper Sadeh LLC
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
August 07, 2024
Via
InvestorPlace
Pharmacosmos Group to Acquire G1 Therapeutics
August 07, 2024
From
G1 Therapeutics; Pharmacosmos
Via
GlobeNewswire
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
July 25, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
July 15, 2024
Via
InvestorPlace
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
July 10, 2024
Via
InvestorPlace
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
June 25, 2024
Via
Benzinga
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
June 24, 2024
Via
InvestorPlace
Exposures
Product Safety
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
June 24, 2024
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
June 24, 2024
Via
Benzinga
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
June 24, 2024
Via
Benzinga
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
June 24, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
June 24, 2024
Via
InvestorPlace
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
June 24, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.